Alemayehu Aberham Abere, Castañeda Mogollón Daniel, Belay Sisay Getie, Tesfa Habtie, Mohon Abu Naser, Balasingam Nirujah, Bayih Abebe Genetu, Ashraf Shoaib, Pillai Dylan R
Department of Medical Parasitology, School of Biomedical & Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Department of Pathology and Laboratory Medicine, Medicine, and Microbiology Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Open Forum Infect Dis. 2025 May 9;12(6):ofaf279. doi: 10.1093/ofid/ofaf279. eCollection 2025 Jun.
According to the World Health Organization, almost two-thirds of the Ethiopian population is at risk of contracting malaria, where infection with accounts for approximately 60% of cases today. The risk of artemisinin resistance spreading from southeast Asia to Africa is a major concern. We conducted a 28-day efficacy trial of artemether-lumefantrine (Coartem) for treatment of uncomplicated malaria (n = 97) in the Gondar area, northwest Ethiopia, from 2017 to 2018. Our results confirmed 100% adequate clinical and parasitologic response, with no parasites observed at day 3 by microscopy. Further analysis of day 0 samples showed the expansion of a mutation R622I to 9.5% from 2.4% of isolates reported 3 years earlier. Closer examination of the R622I mutation is warranted.
根据世界卫生组织的数据，近三分之二的埃塞俄比亚人口有感染疟疾的风险，目前约60%的病例是由[此处原文缺失相关内容]感染引起的。青蒿素耐药性从东南亚传播到非洲的风险是一个主要担忧。2017年至2018年，我们在埃塞俄比亚西北部贡德尔地区进行了一项为期28天的蒿甲醚-本芴醇（科泰复）治疗非复杂性疟疾（n = 97）的疗效试验。我们的结果证实临床和寄生虫学反应充分率达100%，显微镜检查在第3天未观察到寄生虫。对第0天样本的进一步分析显示，一种R622I突变的发生率从3年前报告的2.4%扩大到了9.5%。有必要对R622I突变进行更深入的研究。
